Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARES: Postoperative Opioid Tapering and Pain Management Support
NCT06027099Phase 3Recruiting
- Sponsor
- Stanford University
- Start
- Dec 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tizanidine in opioid use disorder (OUD), chronic pain, back pain and 1 more (3 arms), sponsored by Stanford University. Primary endpoint: Time to Baseline Opioid Use at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
tizanidine
03
Conditions
opioid use disorder (OUD)chronic painback painCervicalgia
Beyond the preview
Go deeper on NCT06027099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027099.